secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2023-01-03T23:59:59+00:00
Accession:  0001140361-23-000030
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech licenses M9241 from Merck KGaA for $10M upfront, up to $116M milestones, 10% royalty
--------------------------------------------------------------------------------

- Exclusive global license for M9241 (PDS0301), a tumor-targeting IL-12 fusion protein, from Merck KGaA, Darmstadt, Germany.
- Upfront consideration: $5M cash plus 378,787 shares valued at $5M (based on Dec 30 close); total $10M.
- Milestone payments: up to $11M development/regulatory, up to $105M commercial; 10% royalty on net sales with step-down provisions.
- Phase 2 triple combination data: median OS 21 months in CPI-refractory pts (historical 3-4 mo); 63% ORR in optimal dose group.
- FDA meeting scheduled to discuss registrational trial for triple combination in recurrent/metastatic HPV-positive cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036123000030/0001140361-23-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036123000030/brhc10046080_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer